Number of pages: 100 | Report Format: PDF | Published date: 01 September, 2022
Historical Years – | Base Year – | Forecasted Years –
Glioma is a kind of tumor that develops in the brain and spinal cord. Glioma begins in the glial cells surrounding the nerve cells and helps in their proper functioning. There are three types of glial cells which have the tendency to produce tumors namely oligodendrocytes, astrocytes, and ependymal cells. Adults with gliomas tend to develop it between the age of 45 and 65. A brain tumor, however, can develop at any age. Ependymomas and pilocytic astrocytoma’s are two forms of gliomas that are more prevalent in children and young adults.
Global Adult Malignant Glioma Therapeutics Market, by Type
Global Adult Malignant Glioma Therapeutics Market, by Therapy
Global Adult Malignant Glioma Therapeutics Market, by Regions
Key Market Trends
The global adult malignant glioma therapeutics market according to type is grouped into glioblastoma multiforme, anaplastic oligodendroglioma, and anaplastic astrocytoma. Among these, the glioblastoma multiforme dominated the market with largest share. The chance of getting glioblastoma is higher in people who have received radiation therapy for leukemia, a fungal scalp infection, or prior brain cancer. In addition, individuals with chromosomal abnormalities on chromosomes 10 or 17 are at higher risk of malignant glioma. Further, the high cost of drugs to treat glioblastoma multiforme is further enhancing the revenue share. For instance, the current standard of care for glioblastoma involves chemotherapy with the temozolomide drug which costs around $108.24. During radiation therapy, temozolomide is typically given every day, and six cycles later. During the maintenance phase it is administered again. Other segments such as anaplastic oligodendroglioma and anaplastic astrocytoma are anticipated to increase in the forecast period due to availability of many drugs in pipeline.
Key Components of the Report
Key Market Players
The key market players operating in malignant glioma therapeutics market are Merck & Co. Inc., F. Hoffman-La Roche Ltd., Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Emcure Pharmaceuticals Ltd., Teva pharmaceutical Industries Limited, and Arbor Pharmaceuticals, LLC among others.
Reasons to Buy this Report
*Insights on financial performance is subject to availability of information in public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.